Pelage Pharmaceuticals
LOS ANGELES, CA · Biotechnology, Healthcare · 10 employees
Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing first-in-class treatments for hair loss. With a focus on stem cell biology and metabolism, Pelage is advancing a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body’s ability to naturally grow hair. Its lead program, PP405, is currently in Phase 2a clinical trials. T
Funding history
- Venture - Series Unknown — $120.0M — Nov 2025
- Series B — $120.0M — Oct 2025
- Venture - Series Unknown — $14.0M — Aug 2024
- Series A — $14.0M — Aug 2024
- Series A — $16.8M — Feb 2024
Recent signals
- Feb 23, 2026: Pelage Pharmaceuticals Appoints Nathan Wheeler as Chief Operating Officer
- Nov 24, 2025: Raised $120.0M in Venture - Series Unknown
- Oct 15, 2025: Raised $120.0M in Series B
- Aug 23, 2024: Raised $14.0M in Venture - Series Unknown
- Aug 13, 2024: Raised $14.0M in Series A
- Feb 27, 2024: Raised $16.8M in Series A
- Jun 28, 2023: Raised $16.7M in Venture - Series Unknown
See plans & pricing → Track Pelage Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.